Immune Systems Advisor

Cold and flu season is not simply about having a thermometer and a box of cold medicine ready. The modern respiratory-virus landscape includes influenza, COVID-19, RSV and other viruses—and the evidence on how we should treat severe influenza is changing. Updated September 2026 • Evidence reviewed from CDC, WHO, Australian Living Evidence Collaboration and the 2026 REMAP-CAP influenza antiviral results Key update for 2026: A major REMAP-CAP randomized trial found that oseltamivir did not improve 90-day survival in critically ill patients with influenza and crossed a prespecified inferiority threshold. Australian interim guidance now recommends against oseltamivir in critically ill adults. This finding is highly important—but it does not mean that oseltamivir should be stopped in every person with influenza. Contents Why cold and flu season matters Cold vs flu: what is the difference? Common symptoms Who is at higher risk? Ho...

Medically reviewed by: OneDayMD Editorial Team | Last updated: August 2026 (includes link to Dr Paul Marik and Dr Justus Hope latest Substack article related to "turbo cancer") For years, clinicians and patients have described a disturbing pattern — cancers appearing suddenly, growing at unexpected speed, or diseases thought stable returning aggressively within weeks or months. A sudden rise in younger people with early onset cancers which are more aggressive with more (and unusual) genetic change has been increasingly noted - colorectal, breast and GI tract cancers seem to lead the way. Some called them “turbo cancers”. In oncology, the phenomenon is known as hyper-progression: cancers that accelerate far more rapidly than expected. Early on, these reports were ignored. They surfaced as scattered cases — isolated anecdotes that were easy to dismiss. One of the first to speak publicly was Belgian immunologist Michel Goldman, whose story was published in...